

## AMENDMENT TO THE CLAIMS

Please amend claims 5-8, 10, 11, 13, 14, 16 and 17; cancel claims 9, 12 and 15; and add new claim 18, as follows:

1. (Original) A polypeptide, derivative or analogue thereof, comprising a tandem repeat of apolipoprotein B or a truncation thereof, characterised in that the tandem repeat or truncation thereof is derived from an HSPG receptor binding region of apolipoprotein B.
2. (Original) The polypeptide, derivative or analogue thereof according to claim 1, wherein the polypeptide, derivative or analogue thereof comprises a tandem repeat which is derived from an apolipoprotein B LDL receptor binding domain cluster B.
3. (Original) The polypeptide, derivative or analogue thereof according to claim 1 comprising a tandem repeat of apoB3359-3367 or a truncation thereof.
4. (Original) The polypeptide, derivative or analogue thereof according to claim 1 comprising the amino acid sequence of SEQ ID No. 1
5. (Currently Amended) The polypeptide, derivative or analogue thereof according to claim 3 ~~or~~ 4, wherein at least one of the first, second, third, seventh, eighth, ninth, tenth, eleventh, twelfth, sixteenth, seventeenth or eighteenth residues is substituted or deleted.
6. (Currently Amended) The polypeptide according to claim 1 of formula:  
abcRKRxyza'b'c'RKRx'y'z' (I)  
wherein  
a and & a' are each ~~=is~~ independently selected from the group consisting of a positively charged residue, which may be ~~selected from either~~ Arginine (R), ~~or~~ Lysine (K) or Histidine (H), ~~Leucine (L), Tryptophan (W), and~~ ~~;-or-~~ is deleted;  
b and & b' are each ~~=is~~ independently selected from the group consisting of Leucine (L), ~~Arginine (R), Lysine (K), and~~ ~~;-or-~~ is deleted;

c and & c' are each ~~is~~ independently selected from the group consisting of Threonine (T),<sub>;</sub> Tryptophan (W), and ~~;~~ or a positively charged residue, which may be ~~selected from~~ Arginine (R),<sub>;</sub> or Lysine (K) or Histidine (H);

x and & x' are each ~~is~~ independently selected from the group consisting of Glycine (G),<sub>;</sub> Tryptophan (W),<sub>;</sub> Leucine (L), and ~~;~~ or a positively charged residue, which may be ~~selected from~~ Arginine (R),<sub>;</sub> or Lysine (K) or Histidine (H);

y and & y' are each ~~is~~ independently selected from the group consisting of Leucine (L),<sub>;</sub> a positively charged residue, which may be ~~selected from~~ Arginine (R),<sub>;</sub> or Lysine (K) or Histidine (H), and ~~;~~ or is deleted; and

z and & z' are each ~~is~~ independently selected from the group consisting of a positively charged residue, which may be ~~selected from~~ Arginine (R),<sub>;</sub> or Lysine (K) or Histidine (H),<sub>;</sub> or Leucine, and ~~;~~ or is deleted.

7. (Currently Amended) The polypeptide, derivative or analogue thereof according to ~~either~~ claim 1 ~~or claim 2~~ comprising the amino acid sequence: LRTRKRGRKLRTRKRGRK (SEQ ID No.2); RTRKRGRKRTRKRGRK (SEQ ID No.3); RTRKRGRRTRKRGR (SEQ ID No.4); LRKRKRLLRKRKRL (SEQ ID No.5); LRKRKRLRKLRLKRKRLRK (SEQ ID No.6); WRWRKRWRKWRWRKRWRK (SEQ ID No.7); RRWRKRWRKWRWRKRWRK (SEQ ID No.34); KRWRKRWRKWRWRKRWRK (SEQ ID No.35); LRWRKRWRKWRWRKRWRK (SEQ ID No.36); HRWRKRWRKWRWRKRWRK (SEQ ID No.37); RWRKRWRKWRWRKRWRK (SEQ ID No.38); RRWRKRWRKRRWRKRWRK (SEQ ID No.39); KRWRKRWRKKRWRKRWRK (SEQ ID No.40); LRWRKRWRKLRWRKRWRK (SEQ ID No.41); HRWRKRWRKHRWRKRWRK (SEQ ID No.42); RWRKRWRKRWRKRWRK (SEQ ID No.43); RWRKRGRKRWRKRGRK (SEQ ID No.44); RTRKRWRKRTRKRGRK (SEQ ID No.45); RWRKRWRKRWRKRWRK (SEQ ID No.46); or RWRKRWRWRKRWRWRKRW (SEQ ID No.47).
8. (Currently Amended) A composition, comprising the polypeptide, derivative or analogue thereof according to ~~any preceding claim 1~~ for use as a medicament.

Claim 9 (Canceled).

10. (Currently Amended) A method of preventing and/or treating a viral infection, comprising administering to a subject in need of treatment a therapeutically effective amount of the a polypeptide, derivative or analogue according to claim 1 ~~any of claims 1 to 7~~.
11. (Currently Amended) An agent adapted to increase ~~capable of increasing~~ the biological activity of the a polypeptide, derivative or analogue according to claim 1 ~~any of claims 1 to 7, for use as a medicament~~.

Claim 12 (Canceled).

13. (Currently Amended) A nucleic acid sequence encoding the a polypeptide, derivative or analogue according to claim 1 ~~any of claims 1 to 7~~.
14. (Currently Amended) A composition, comprising the nucleic acid according to claim 13, ~~for use as a medicament~~.

Claim 15 (Canceled).

16. (Currently Amended) The A nucleic acid according to claim 13, wherein the nucleic acid comprises a nucleotide sequence as set out as SEQ ID No.8 (apoB3359-3367), SEQ ID No.9 (GIN 16), SEQ ID No.10 (GIN 35), SEQ ID No.11 (GIN 36), SEQ ID No.12 (GIN 37), SEQ ID No.13 (GIN 38), or SEQ ID No.14 (GIN 33).
17. (Currently Amended) A method of preventing and/or treating a viral infection, comprising administering to a subject in need of treatment a therapeutically effective amount of the a nucleic acid according to claim 13 ~~any of claims 13 to 16~~.

18. (New) The polypeptide, derivative or analogue thereof according to claim 4, wherein at least one of the first, second, third, seventh, eighth, ninth, tenth, eleventh, twelfth, sixteenth, seventeenth or eighteenth residues is substituted or deleted.